Description
Anti-Fibrinogen Antibody, Non-Fucosylated (BioBet-879ZP) is a mouse monoclonal IgG antibody against Fibrinogen. This product is an ADCC enhanced antibody produced by our Afuco™ platform.
Antibody Indication
Cancer
Classification
Therapeutic antibody; biobetter
Cooperation Seeking
Creative Biolabs is interested in collaborating with potential partners (include but not limit to major pharma or biotech firms) to further co-develop ADCC-enhanced Fibrinogen antibody. For commercial partners interested in our ADCC-enhanced therapeutic antibodies, Creative Biolabs welcomes collaboration. Here are two ways for your choice, and please contact us for more details.
1) Collaborate with us and co-develop the programs from discovery phase to IND enabling. Costs will be shared.
2) Become a licensed candidate of our programs.
Looking forward to cooperating with you in the near future.
Full Name
fibrinogen beta chain
Background
The protein encoded by this gene is the beta component of fibrinogen, a blood-borne glycoprotein comprised of three pairs of nonidentical polypeptide chains. Following vascular injury, fibrinogen is cleaved by thrombin to form fibrin which is the most abundant component of blood clots. In addition, various cleavage products of fibrinogen and fibrin regulate cell adhesion and spreading, display vasoconstrictor and chemotactic activities, and are mitogens for several cell types. Mutations in this gene lead to several disorders, including afibrinogenemia, dysfibrinogenemia, hypodysfibrinogenemia and thrombotic tendency. Alternatively spliced transcript variants encoding different isoforms have been found for this gene.
Alternative Names
FGB; fibrinogen beta chain; HEL-S-78p; fibrinogen, B beta polypeptide; epididymis secretory sperm binding protein Li 78p
Cellular Localization
Extracellular region or secreted
Involvement in Disease
Diseases associated with FGB include Afibrinogenemia, Congenital and Dysfibrinogenemia, Congenital.
Related Pathways
Its related pathways are Activated TLR4 signalling and RET signaling.
Function
It is cleaved by the protease thrombin to generate monomers, which polymerize with fibrinogen (FGA) and fibrinogen (FGG) to form an insoluble fibrin matrix. As one of the main components of blood clots, fibrin plays an important role in hemostasis. In addition, it has the function of stabilizing damage and guiding cell migration in the early stage of wound repair. It was initially thought to be essential for platelet aggregation, which was based on in vitro anticoagulation studies. However, subsequent studies have shown that it is not necessary for the formation of blood clots in the body. Enhance the expression of SELP in activated platelets. The mother's fibrinogen is essential to a successful pregnancy. Fibrin deposition is also associated with infection, and it can prevent ifng-mediated bleeding. It is also possible to promote antibacterial immune responses through innate and T cell-mediated pathways.
Post-translational modifications
Conversion of fibrinogen to fibrin is triggered by thrombin, which cleaves fibrinopeptides A and B from alpha and beta chains, and thus exposes the N-terminal polymerization sites responsible for the formation of the soft clot. The soft clot is converted into the hard clot by factor XIIIA which catalyzes the epsilon-(gamma-glutamyl)lysine cross-linking between gamma chains (stronger) and between alpha chains (weaker) of different monomers.
Biologic Classification
Protein Based Therapies
Monoclonal antibody (mAb)
Description
This is an anti-fibrin antibody that reacts with fibrin only, and not fibrinogen, and then attached an anticancer agent (ACA) to the antibody. Thus, the immunoconjugate did not create an immune complex in the blood stream and was selectively accumulated to fibrin clots in the tumor stroma to create a scaffold, from which effective sustained release of the ACA occurred. This new cancer stroma-targeting therapy may result in an increased duration of drug exposure and be a highly effective new therapy, particularly for refractory, stroma-rich cancers.
Antibody Indication
Cancer
